



Long-term outcome of kidney transplantation from deceased donors with early graft dysfunction: a single-center analysis

KEYWORDS

Kidney transplantation, Early graft dysfunction, Graft survival

Ji Shu-Ming

National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210016, China

Xie Ke-Nan

National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210016, China

Cheng Dong-Rui

National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210016, China

Wen Ji-Qiu

National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210016, China

Chen Jin-Song

National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210016, China

ABSTRACT

Objective The purpose of this study was to investigate the correlation factors for early graft dysfunction after kidney transplantation, and the effects on long-term graft survival.

Methods Two hundred and fifty-one recipients of first cadaveric renal graft were divided into four groups according to the history of acute rejection (AR) and the concentration of serum creatinine in 6 months (SCr 6mo) after transplantation: Group A and B, having no history of AR with SCr 6mo <130.0 μmol/L in the former and ≥130.0 μmol/L in the latter, and groups C and D having the history of AR with SCr 6mo <130.0 μmol/L in the former and ≥130.0 μmol/L in the latter. All groups had the same immunosuppressive protocol.

Results 10th day after operation in groups A and C maintained, while the serum creatinine level in group B and D were obviously elevated, which was correlated with acute tubular necrosis (ATN), IgA nephritis, donor's age, postoperative hypotension, AR times and the dosage of cyclosporine A. The one- and three-year survival rate of renal graft in group D was significantly lower than groups A, B and C.

Conclusion Acute tubular necrosis was the commonest cause for renal graft dysfunction after renal transplantation. The damage to the kidney in the process of renal removal, ischemia-reperfusion and high dose of cyclosporine A at early stage might affect the recovery of the early renal function. The dysfunction of early renal dysfunction after operation would affect the renal graft long-term survival in patients having AR in 6 months after operation.

INTRODUCTION

With the advent and extensive application of new potent immunosuppressive agents, short-term graft survival has improved substantially in renal transplant recipients, long-term graft survival has not improved over the last decades^[1,2,3,4]. An early graft dysfunction has still remained a major long-term clinical problem in renal transplantation^[5,6]. Several factors affect renal function immediately after transplantation. Although experimental studies have shown the crucial role of ischemia-reperfusion injury in early graft dysfunction, the relative contribution of donor- or recipient-related factors to the development of graft dysfunction is still debated. This study has investigated the correlative factors for early graft dysfunction after renal transplantation and the effects on long-term graft survival.

MATERIALS AND METHODS

Patients Between January 1, 2004 and June 30, 2011, two hundred and sixty-one primary cadaveric renal transplants were performed in recipients >18 years old at the Jinling Hospital, we eliminated 10 early graft losses due to technical failure from this analysis. Recipient demographics of the study population (n=251) and listed in table 1.

Immunosuppression All recipients had the same immunosuppressive protocol^[7]. Briefly, all patients received induction immunosuppression immediately after the transplant consisting of prednisone (Pred.), mycophenolate mofetil

(MMF), cyclosporine (CsA) or tacrolimus (FK506). When the serum creatinine reached a level of 222.0 μmol/L or lower, patients were started on calcineurin inhibitors (CNIs) and then were maintained chronically on Pred, MMF. The dose of CsA was adjusted by CsA trough concentrations of 200-400 μg/L up to month 4 and at 80-200 μg/L thereafter. The dose of FK506 was adjusted by FK506 trough concentrations of 6-8 μg/L up to month 4 and at 4-5 μg/L thereafter.

Diagnosis and treatment of rejection All episodes of acute rejection (AR) were diagnosed on an elevation of serum creatinine and pathologic evidence of rejection by Banff's classification^[8]. Rejection episodes (all biopsy proven) were treated by intravenously steroid pulse therapy (methylprednisolone and 500 mg/day, for 3 days). Histologically severe rejections and all steroid-resistant rejections were treated with a 7- to 10-day course of rabbit antithymocyte globulin (ATG, 100 mg/day, v.d.).

Graft monitoring Monitoring of 10 days and 6 months after renal transplantation serum creatinine level changes. Early graft dysfunction was defined as serum creatinine evaluated at 10 days (SCr_{10d}) after transplantation^[9]. Dialysis was performed as needed in the posttransplant period, according to the patients' clinical status and laboratory parameters. Delayed graft function (DGF) was defined as the need for at least one dialysis session during the first 7 days after transplant^[10]. The return of a patient to dialysis, on a

permanent bases, was considered to be an allograft failure. Graft survival was censored at the time of patient death.

Statistical analyses Survival times were calculated from a life table using the product-limit method. Pairwise evaluation of means and proportions was performed with the t test and chi-square test as appropriate.

RESULTS

Patient characteristics The period of follow up was 3.5 years and by study design, all patients were alive and maintained allograft function for at least 6 months after the treatment. During this period of time, recipient characteristics of the study and listed in table 2. In these studies (Table 3), patients were divided into four groups according to (1) history of AR during the first 6 months after transplantation, and (2) concentration of serum creatinine at 6 months after transplantation ($SCr_{6mo} < \text{or} \geq 130.0 \mu\text{mol/L}$).

Correlative factors of the early graft dysfunction Table 4 displays the donor and recipient characteristics and the function of the allograft immediately after the transplant in these four groups of patients. As can be seen, there were no significant differences among these groups in recipient age, cold ischemia time and level of CDC. SCr level at 10th day after operation in groups A and C maintained normal, while recipients with an elevated SCr_{10d} (Group B and D) had received kidneys from older donors, were more likely to be the donor of IgA nephropathy, and also were heavier than patients with a $SCr_{10d} < 130.0 \mu\text{mol/L}$. Furthermore, a significantly higher percentage of patients in group D required dialysis after the transplant compared with the other groups of patients.

Predictive value of a SCr_{10d} after transplantation Based on this observation (Table 5), we investigated the implications of the SCr_{10d} concentrations for graft prognosis. However, an elevated SCr_{10d} correlated with other potential risk factors for graft survival including: donor's age, IgA nephritis and hypotension during operation; and posttransplantation factors such as acute tubular necrosis (ATN), acute rejection and the dosage of CsA.

Relationship between acute rejection and early graft dysfunction The data shown above may suggest that in patients with acute rejection and elevated SCr_{6mo} (group D) the allograft dysfunction preceded the AR episode, because these patients already had an elevated SCr_{10d} after transplant. Group D showed the relationship between the occurrence of AR and the elevation in serum creatinine concentration. In 68% of these patients, the serum creatinine was higher at 6 months after transplantation, after AR, than at 10 days after transplantation ($SCr_{10d} 159.1 \pm 88.6 \mu\text{mol/L}$, $SCr_{6mo} 265.2 \pm 102.6 \mu\text{mol/L}$, respectively, $P < 0.0001$). In contrast, 32% of group D patients had a SCr_{10d} that was greater than or equal to the SCr_{6mo} ($283.1 \pm 107.5 \mu\text{mol/L}$ and $211.4 \pm 94.1 \mu\text{mol/L}$) indicating that in these patients renal allograft dysfunction preceded the AR episodes.

Graft survival Graft survival for patients in groups A and B did not differ significantly (Fig. 1). It should be noted that plots describing graft survival in these two groups of patients are superimposable during the first 3 years after the transplant but tend to diverge beyond that point. Graft survival was also not significantly different between patients in group A and C. In contrast, the one- and three-year survival rate of renal graft in group D was significantly lower

than groups A, B and C.

DISCUSSION

These studies suggest that the association between decreased early graft function and shortened graft survival is due to associations between the early allograft dysfunction and the pre-transplant and post-transplant risk factors^[12]. ATN was the commonest cause for renal graft dysfunction after renal transplantation^[13]. The damage to the kidney in the process of renal removal, ischemia-reperfusion and high dose of cyclosporine A at early stage might affect the recovery of the early renal function^[14]. Shu-Ming Ji et al^[11] suggested clinical features of the recipients which received from donor kidney with glomerular mesangial proliferation and marked diffuse granular IgA deposition: edema, proteinuria, microhematuria, hypoalbuminemia, hypertension, and delayed graft function. The presence of IgA deposits on donated kidney, by a possible increase of the immunogenicity of these kidneys, might be a cause of increased rejection.

The SCr_{10d} is an indicator of risk factors from both the donor and recipient, and an elevated SCr_{10d} predicts a higher risk of acquiring additional risk factors early transplantation. Patients with an elevated SCr_{10d} here a higher risk of AR than patients with lower SCr_{10d} and this observation is consistent with other studies demonstrating a correlation between early allograft damage and risk for rejection. The reason for this relationship is not entirely clear but several explanations can be suggested. Experimental and clinical studies have shown that early allograft damage may alter antigenic expression and cytokine production by graft cells that predispose to AR^[15,16]. In addition, as shown here, patients with elevated SCr_{10d} receive less CsA early after transplantation than patients with lower SCr_{10d} . This finding most likely indicates that patients with reduced renal function are particularly susceptible to the nephrotoxic effects of CsA, which limits the amount of drug that these patients can receive. It is indeed possible that the use of lower dose of CsA in patients with elevated SCr_{10d} places these patients at a higher risk for AR and indeed previous studies noted a relationship between CsA levels during the first few months after transplantation, risk of AR, and allograft survival.

In conclusion, the dysfunction of early renal function after operation would affect the renal graft long-term survival in patients having AR in 6 months after operation. Graft dysfunction predicts poor graft survival only when associated with AR. Similarly, AR predicts a poor renal allograft survival only when associated with graft dysfunction.

Table 1. Recipient demographics (n=251)

Male/female	155/96
Mean age at transplantation SD(yr.)	38.6±15.1
Cold ischemia time (hr.)	21.5±7.8
CDC* (%)	6.7±1.6
PRA* (%)	25.7±10.8

*CDC: complement dependent cytotoxicity, PRA: panel reaction antibody

Table 2. Recipient characteristics of the study for at least 6 months after transplantation

Outcome	n	%
SCr _{10d} ↑	72	28.7
Donor IgA nephropathy ^[11]	31	12.4
Hypotension during operation	27	10.8
DGF	31	12.4
acute rejection	46	18.3
SCr _{6mo} ↑	63	25.1
Patients died	18	7.2
Graft lost	19	7.6

Table 3. Classification of patients according to the episodes of acute rejection during the first 6 mo. of transplantation and the concentration of SCr_{6mo}.

Groups	n(%)	Acute rejection (mean±SD)	SCr _{6mo} (umol/L, mean±SD)
A	170(67.7)	No	< 130.0(92.6±16.5)
B	35(13.9)	No	≥ 130.0(203.3±26.5)
C	18(7.1)	Yes(1.2± 0.5)	< 130.0(112.5±21.4)
D	28(11.2)	Yes(1.9± 1.0)	≥ 130.0(256.4±10.6)

Table 4. Pretransplant and early posttransplant variables in patients classified according to acute rejection number and SCr_{6mo}.

Relative factors	Group A (n=170)	Group B (n=35)	Group C (n=18)	Group D (n=28)	P Value
Donor					
Age(years)	23.6±2.3	38.7±2.2*	24.1±2.4	24.9±3.6	<0.001 ^a
Hot ischemia time (min)	6.3±1.9	6.4±1.9	6.1±1.6	6.0±1.7	>0.05
Cold ischemia time(hr)	20.6±6.8	20.8±5.6	21.1±7.3	20.3±7.1	>0.05
IgA nephropathy(%)	2(1.2)	18(51.4)*	5(27.8)	6(21.4)	<0.05 ^a
Recipient					
Age(years)	36.3±5.4	38.1±5.1	39.2±6.3	38.9±5.4	>0.05
Gender(man,%)	100(58.8)	28(80.0)**	10(55.6)	17(60.7)	<0.001 ^a
CDC ¹ (%)	6.3±1.3	6.8±1.4	6.2±1.3	6.4±1.4	>0.05
PRA ² (%)	15.3±4.9	16.7±5.1	25.7±7.8*	29.8±8.9*	<0.001 ^e
Hypotension in OP. ³ (%)	2(1.2)	14(40.0)*	1(5.6)	10(35.7)*	<0.001 ^b
Early posttransplant					
Scr _{10d} (umol/L)	132.6±53.0	215.5±109.8*	159.1±88.9	274.0±105.6*	<0.001 ^b
DGF ⁴ (%)	2(1.2)	15(42.9)*	5(27.8)	9(32.1)*	<0.005 ^b
ATN ⁵ (%)	2(1.2)	7(20.0)*	1(5.6)	3(10.7)*	<0.01 ^b
AR ⁶ > 1 [‡] (%)	0	0	5(27.8)	15(53.6)*	<0.01 ^b
ACR ⁷ (%)	0	0	14(77.8)*	5(17.9)	<0.001 ^c
AVR ⁸ (%)	0	0	4(22.2)	23(82.1)*	<0.001 ^d

a:Group B v.s other groups; b:Group B and Group D v.s Group A and Group C; c: Group D v.s Group C; d: Group C v.s Group D; e: Group C, Group D v.s Group A, Group B.

reactive antibodies; ³ OP:operation; ⁴ DGF:depayed graft function; ⁵ ATN:acute tubular necrosis; ⁶ AR:acute rejection; ⁷ ACR:acute cellular rejection; ⁸ AVR:acute vascular rejection

¹CDC: complement dependent cytotoxicity; ²PRA: panel

Table 5. The relationships between the SCr_{10d} and pre-,posttransplant variables

Pretransplant SCr _{10d}			Posttransplant SCr _{10d}		
	r value	P value		r value	P value
Donor age (>40yr.)	0.1701	< 0.0001	ATN	0.1309	< 0.0001
Cold ischemia time	0.5621	>0.05	First rejection	0.1703	< 0.0001
Donor IgA nephropathy	0.2120	< 0.001	CsA dosage	- 0.2646	< 0.001
Hypotention during op.	0.2112	< 0.001	Scr _{6mo}	0.4728	< 0.0001




Figure1. Graft survival for patients in the groups

REFERENCE

1. Mirzaee M, Azmandian J, Zeraati H, et al. Short-term and long-term survival of kidney allograft: cure model analysis. *Iran J Kidney Dis.* 2014;8(3):225-230. | 2. Papachristou E, Provatopoulou S, Savvidaki E, et al. Outcome of transplantation in renal allograft recipients from cadaveric donors with standard and expanded criteria: a single-center experience. *Transplant Proc.* 2014;46(9):3172-3174. | 3. Keith D, Patrie JT. Short-term kidney transplant outcomes among African American recipients do not predict long-term outcomes: donor pair analysis. *Clin Transplant.* 2011;25(1):69-76 | 4. Boratyńska M, Wakulenko A, Klinger M, et al. Chronic allograft dysfunction in kidney transplant recipients: long-term single-center study. *Transplant Proc.* 2014;46(8):2673-2677. | 5. Sumrani N, Delaney V, Daskalakis P, et al. The detrimental effect of early rejection on long-term renal allograft outcome. *Transplant Proc.* 1992;24:1750-1752 | 6. Shu-ming JI, Guang YIN, Li-Ping YIN, et al. Correlation factors for early graft dysfunction and prognosis after cadaver renal transplantation. *Chin J Organ Transplant* 1999;20(3):138-140 | 7. Shu-ming JI, Hui-ping Chen, Qing-wen Wang, et al. Clinical and pathological research of acute vascular rejection in renal transplantation. *J Nephrol Dialy Transplant* 1998;7(1):25-30 | 8. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. *Kidney Int.* 1999;8:1930 | 9. Cosio FG, Qiu W, Henry ML, et al. Factors related to the donor organ are major determinants of renal allograft function and survival. *Transplantation* 1996;62(11):1571-1576 | 10. Sanfilippo F, Vaughn WK, Spees EK, et al. The detrimental effects of delayed graft function in cadaver renal transplantation. *Transplantation* 1984;38:643 | 11. Shu-Ming JI, Min LU, Jin-Song CHEN, et al. The fate of glomerular mesangial IgA deposition in the donated kidney after allograft transplantation. *Clin Transplantation* 2004;18: 536-540 | 12. Cesca E, Ghirardo G, Kiblawi R, et al. Delayed graft function in pediatric deceased donor kidney transplantation: Donor-related risk factors and impact on two-yr graft function and survival: A single-center analysis. *Pediatr Transplantation* 2014; 18: 357-362 | 13. Bernd Schröppel and Christophe Legendre. Delayed kidney graft function: from mechanism to translation. *Kidney International* 2014;86: 251-258 | 14. Ji Shuming and CHEN Jinsong. Research progress of donation after cardiac death and renal ischemia reperfusion injury. *J Nephrol Dialy Transplant* 2014;23(5):486-490 | 15. Ji Shu-Ming, Chen Jin-Song, Wen Ji-Qiu, et al. Borderline changes in renal allograft protocol biopsies: intensive therapy and graft outcome. *Indian Journal of Applied Research.* 2015;5(2): 509-511 | 16. Fuquay R, Renner B, Kulik L, et al. Renal ischemia-reperfusion injury amplifies the humoral immune response. *J Am Soc Nephrol.* 2013;24(7):1063-1072 |